Category: 1206487-35-5

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1206487-35-5,4,6-Dibromopyridazin-3-amine,as a common compound, the synthetic route is as follows.

To a stirred solution of 4-bromo-6-bromopyridazin-3-amine (3a), (0.20 g, 0.79 mmol) in DML (5 mL) were ethyl 2-(3,8-diazabicyclo[3.2.1]octan-8-yl)acetate hydrochloride (0.278 g, 1.11 mmol ) and DIPEA (0.7 mL, 3.95 mmol) at RT and stirred for 16 h at 90 C under nitrogen atmosphere. Then the reaction mixture was quenched with cold water (20 mL) and the brown solid obtained was washed with diethyl ether, filtered and dried under vacuum. The same procedure was repeated four times to afford pure title compound (0.155 g, Yield : 55 %). 1H NMR (400 MHz, DMSO-d6): d 6.96 (s, 1H), 5.76 (s, 2H), 4.15-4.03 (m, 2H), 3.37-3.29 (m, 2H), 3.19 (s, 2H), 3.16-3.14 (m, 2H), 2.83-2.80 (m, 2H), 1.85 (s, 4H), 1.23-1.13 (m, 3H); LC-MS: m/z 371.1 (M+l)+., 1206487-35-5

Big data shows that 1206487-35-5 is playing an increasingly important role.

Reference£º
Patent; AURIGENE DISCOVERY TECHNOLOGIES LIMITED; SASMAL, Sanjita; SAMAJDAR, Susanta; MUKHERJEE, Subhendu; ABBINENI, Chandrasekhar; (260 pag.)WO2019/207538; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

1206487-35-5, 4,6-Dibromopyridazin-3-amine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 2-bromo- 1 -((lr,3 r)-3- (quinolin-2-yl)cyclobutyl)ethanone (1.56 g, 4.62 mmol, prepared using themethod described in Example 1, step C) and 4,6-dibromopy-ridazin-3-amine (1.17 g, 4.62 mmol) in DMF (10 mE) wasstirred at rt for 3 days. The reaction mixture was poured intowater (200 mE), and extracted with EtOAc (2×200 mE). The combined organic layers were washed with saturated NaHCO3 and brine, dried over Na2 SO4, filtered, and concentrated. The residue obtained was purified by flash chromatography on silica gel (0-40% EtOAc/heptane) to obtain 2-((lr, 3r)-3-(6,8-dibromoimidazo[ 1 ,2-b]pyridazin-2-yl)cyclobutyl)quinoline as a yellow oil. ?H-NMR (400 MHz, CDC13) oe (ppm): 8.10 (dd, J=8.3, 4.8 Hz, 2H), 7.98 (s, 1H), 7.79 (d, J=8.1 Hz, 1H), 7.70 (t, J=7.8 Hz, 1H), 7.47-7.53 (m, 1H), 7.44 (s, 1H), 7.38 (d, J=8.6 Hz, 1H), 4.01-4.10 (m, 1H),3.89-3.99 (m, 1H), 2.96-3.08 (m, 2H), 2.75-2.86 (m, 2H).

1206487-35-5, The synthetic route of 1206487-35-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Janssen Pharmaceutica, NV; Player, Mark R.; Meegalla, Sanath K.; Illig, Carl R.; Chen, Jinsheng; Wilson, Kenneth J.; Lee, Yu-Kai; Parks, Daniel J.; Cheung, Wing S.; Huang, Hui; Patch, Raymond J.; US2014/364413; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem